1 Department of Clinical Epidemiology and Biostatistics, Academic Medical Centre, University of Amsterdam, Amsterdam, 2 Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, 3 Department of Medical Informatics, Academic Medical Centre, University of Amsterdam, Amsterdam, 4 Department of Nephrology, Academic Medical Centre, University of Amsterdam, Amsterdam and 5 Dianet Dialysis Centres, Amsterdam and Utrecht, The Netherlands 6 Apperloo A. J., Barendregt J. N. M., Birnie R. J., Boekhout M., Boer W. H., Bommel E. F. H. van, Büller H. R., Charro F. Th. de, Doorenbos C. J., Dorp W. T. van, Es A. van, Fagel W. J., Feith G. W., Franssen C. F. M., Frenken L. A. M., Geelen J. A. C. A. van, Geerlings W., Gerlag P. G. G., Gorgels J. P. M. C., Grave W., Huisman R. M., Jansen M. A. M., Jie K., Koning-Mulder W. A. H., Koolen M. I., Kremer Hovinga T. K., Lavrijssen A. T. J., Mulder A. W., Parlevliet K. J., Rosman J. B., Saase J. L. C. M. van, Schonk M. J. M., Schuurmans M. M. J., Stevens P., Tijssen J. G. P., Valentijn R. M., Vastenburg G., Verburg C. A., Verhagen C. E., Verstappen V. M. C., Vincent H. H. and Vos P.
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Methods. The NECOSAD study on the adequacy of dialysis started in 1993. This prospective multi-centre study included ESRD patients older than 18 years who started HD or PD as the first RRT. We analysed the distribution of age, gender, primary renal disease and co-morbidity, the mean residual renal function and the mean dialysis-Kt/Vurea at 3 months in 1569 consecutive patients by calendar year of initiation dialysis.
Results. Age, gender, primary renal disease and number of co-morbid conditions at the start of dialysis remained stable over time between 1993 and 2000. The mean renal Kt/Vurea at 3 months increased from 0.5 in 1993 to 0.8 per week in 2000 (P<0.01). An upward trend remained after adjustment for patient characteristics and dialysis centre. The total Kt/Vurea at 3 months increased from 3.3 in 1993 to 3.7 per week in 2000 in HD (P<0.01) and from 2.0 in 1993 to 2.3 per week in 1999 in PD patients (P<0.01). An upward trend in the dialysis-Kt/Vurea was found after adjustment for renal Kt/Vurea (HD: +0.3 per week, P=0.06; PD, +0.2 per week, P<0.05).
Conclusions. These results indicate a tendency towards earlier introduction of RRT and higher doses of dialysis in The Netherlands. Possible effects of this development on mortality, morbidity, quality of life and the balance between costs and benefits need further investigation.
Keywords: adequacy; co-morbidity; DOQI guidelines; patient characteristics; renal replacement therapy; time trends
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The aim of the present study was to examine whether a time trend was present in the initiation and the dose of dialysis in ESRD patients in recent years in The Netherlands. We also examined whether the distribution of patients in terms of age, gender, co-morbidity and primary kidney disease changed in the same years and whether differences in patient characteristics by calendar year of starting dialysis might explain time trends in dialysis practice.
![]() |
Subjects and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The data of 1319 NECOSAD-2 participants were included in the present analysis. Thirty-seven patients died within 3 months after the start. In 23 patients the participation was finished before the 3-month visit (mainly because of refusal). In 12 patients no data from the 3-month visit were available.
Data collection procedures
Data on demography, primary kidney disease and co-morbidity were collected at the time of entry in the study. Data on residual renal function, nutritional status, biochemistry and dialysis characteristics (current modality, Kt/Vurea, ultrafiltration) were collected 3 months after the start of RRT (baseline visit). For a subgroup of NECOSAD-2 patients detailed information on residual renal function and nutritional status just prior to or at the time of initiation of RRT was available (0-month visit). Primary kidney disease was classified according to the codes of the European Renal Association-Dialysis and Transplantation Association (ERA-EDTA) [10]. Based on the number of co-morbid conditions a patient was classified according to the Davies' co-morbidity index as having no, intermediate, or severe co-morbidity [11]. To monitor renal function both urea and creatinine were measured in simultaneously obtained plasma and urine samples. Residual renal function was expressed as residual GFR (rGFR), calculated as the mean of renal creatinine and urea clearance, adjusted for body surface area (ml/min/1.73 m2), and as weekly renal Kt/Vurea, in which V was calculated according to Watson et al. [12]. The contribution of renal function to fluid balance was estimated from a 24-h urine collection in PD patients and from an inter-dialytic urine collection in HD patients. Urea clearance by dialysis was expressed as weekly dialysis Kt/Vurea. Peritoneal Kt/Vurea was calculated from a 24-h dialysate collection and the dialysate and plasma urea concentrations. HD Kt/Vurea was estimated according to the second-generation Daugirdas formula based on one plasma urea measurement before and one after the dialysis session, the ultrafiltration and the duration of the session [13].
The daily protein intake shortly preceding or at the time of the 0-month visit was calculated from the urea excretion in the urine [normalized protein equivalent of nitrogen appearance (nPNA)], according to Bergström et al. [14] and normalized to actual body weight.
Statistical analysis
We examined the differences in patient and treatment characteristics at the 3-month visit by calendar year of initiation of dialysis and assessed whether the possible differences might fit into a time trend. In the univariate analyses, means and percentages were calculated by year of initiation of RRT and tested by means of the F-test (ANOVA) and the 2-test when appropriate. The MantelHaenszel
2-test for trends was used to test whether yearly differences in percentage might fit into a time trend. In a multivariate regression analysis the possible associations between the year of initiation of RRT on the one hand, and rGFR, renal Kt/Vurea, urine production, and dialysis-Kt/Vurea at 3 months on the other, were adjusted for age, gender, primary kidney disease and number of co-morbid conditions, as these factors might confound the time trends of interest. The renal Kt/Vurea and the body mass index (BMI) were also included in the multivariate model for the time trend in the dialysis-Kt/Vurea. The renal Kt/Vurea was included because a higher residual renal function will often lead to a lower prescribed Kt/Vurea delivered by dialysis. Consequently, a time trend towards a higher residual renal function at baseline may lead to a non-independent decline in the dialysis dose or a spurious absence of a time trend in the dialysis dose. Furthermore, a possible time trend in the BMI may influence the time trend in dialysis dose, as urea clearance by dialysis is normalized to the urea distribution volume. Calendar time of initiation of RRT was categorized into 6 calendar years (19931994, 19972000) to enable the consideration of time trends other than strictly linear ones. The number of recruiting dialysis centres and the number of recruited patients within a dialysis centre varied in the course of the NECOSAD study and this might confound the time trends of interest because of possible differences in patient care among dialysis facilities. Therefore the possible effect of dialysis centre on dialysis practice was taken into account by including the centre as a categorized variable in the statistical models. The model for the dialysis-Kt/Vurea was designed for HD and PD patients separately. The overall effect of the inclusion of calendar year of initiation of RRT in the multivariate models was tested by means of the partial F-statistic.
We examined whether the percentage of timely starters, as defined on the basis of the DOQI guidelines, increased in recent years. This was done in a subgroup of NECOSAD-2 patients in whom sufficient data on renal function and nutritional status at the 0-month visit (i.e. the start of dialysis) were available. Patients were classified as timely starters when the renal Kt/Vurea was above 2.0 per week or the nPNA was above 0.8 g/kg and the BMI was at least 20 kg/m2 at the time of initiating RRT [15]. Differences in the number of timely starters by year of initiating RRT were tested by means of the 2-test.
Finally, the mortality rates (number of deaths per year of follow-up) in the first year following the 3-month visit were calculated by year of initiation of RRT (19932000). In a multivariate Poisson regression model differences in mortality rates by calendar year were adjusted for the effects of age, gender, co-morbidity, primary kidney disease and blood concentration of albumin at baseline. The contribution of year of initiation of RRT to the regression model was tested by means of the likelihood ratio-statistic (type 3).
All analyses were performed with SAS statistical software, version 6.12. A P value of 0.05 was regarded as statistically significant. A P value from 0.05 to 0.15 was regarded as borderline significant.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
Residual renal function by year of initiation of dialysis
Univariate. The rGFR, renal Kt/Vurea and urine production at the 3-month visit increased in the period 19932000 among both HD and PD patients (Table 2). The mean renal Kt/Vurea at 3 months increased from 0.51 in 1993 to 0.80/week in 2000 when the data of HD and PD patients were put together (P<0.01).
|
|
Dose of dialysis by year of initiation dialysis
Univariate. No differences in the mean dialysis Kt/Vurea by year of initiation of RRT were observed in HD patients (Table 2). The differences in the mean dialysis-Kt/Vurea by year of initiation of RRT reached the level of statistical significance in PD patients (P<0.05). However, this finding was due to the decline in the mean dialysis-Kt/Vurea between 1999 and 2000. When the data of PD patients in 2000 were excluded from the statistical inference, no differences by year of initiation could be established (P=0.2116; data not shown). Differences in total Kt/Vurea (renal+dialysis) at 3 months by year of initiation of RRT were found among both HD and PD patients (P<0.01) (Table 2
). These differences indicated higher values of total Kt/Vurea in recent years. The percentage of HD patients with a total Kt/Vurea up to the DOQI standard (
3.6/week) increased from 32% in 1993 to 59% in 2000 (P=0.007). Such a trend towards a higher percentage of patients who were treated up to the DOQI standard (total Kt/Vurea
2.0/week) was also suggested in PD patients (P=0.065). However, the percentage of PD patients with a total Kt/Vurea up to the DOQI standard decreased from 66.7% in 1999 to 50.0% in 2000. A trend towards higher values became more apparent when the data of PD patients in 2000 were excluded from the analysis (P=0.0033).
Multivariate. Changes over time in the dialysis Kt/Vurea adjusted for patient characteristics (including renal Kt/Vurea and BMI) and dialysis centre are presented in Table 4. An upward trend was suggested in both HD and PD patients. However, in PD patients the dialysis Kt/Vurea decreased in 2000. When the data of PD patients in 2000 were excluded from the analysis, the change over time still reached the level of statistical significance (P=0.026, data not shown). No effect of year of initiation of RRT could be established when the residual renal Kt/Vurea was excluded from the multivariate regression models (HD, P=0.279; PD, P=0.246, data not shown).
|
Mortality rates by year of initiation dialysis. The crude mortality rate in the first year following the 3-month visit in 1993/1994 (NECOSAD-1) was 0.134/person year. A small increase to 0.163/person year in 2000 was noted, but differences by year of start dialysis were not statistically significant (P=0.9326). Adjusting the yearly differences for the effects of age, gender, co-morbidity, primary kidney disease, serum albumin and body mass index did not modify this result (P=0.6192) (Figure 1).
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In each calendar year the distribution of age, gender and primary renal disease in the NECOSAD population was similar to that of all new dialysis patients in 19932000 in The Netherlands (data from the national registry on renal replacement therapy in The Netherlands, RENINE, not shown) [10]. Hence, this agreement strongly suggests that the NECOSAD study population was a representative sample of all new dialysis patients in The Netherlands.
Our results are in accordance with reports from the USA and Canada, in which time trends towards an earlier start of dialysis and a higher dialysis dose were demonstrated [59]. For instance, in the US Renal Data System (USRDS) an increase of the estimated GFR at the initiation of RRT from 7.1 in 1995 to 8.3 ml/min in 2000 was found (http://www.usrds.org). In a special USRDS study, it was shown that the delivered Kt/Vurea increased from 0.91/HD session in 1987 to 1.18/HD session in 1997, suggesting that the increasing emphasis on adequate dialysis had started to exert its influence even before the publication of the DOQI guidelines [7]. In the Peritoneal Dialysis-Core Indicators Study (PD-CIS) the weekly Kt/Vurea increased from 1.9 to 2.3 and the frequency of achievement of minimal DOQI adequacy criteria increased from 23 to 63% in a random sample of the 19952000 US PD population [9].
It can be questioned whether the DOQI guidelines on the start and the dose of dialysis should be implemented in other countries without any modification. Guidelines may require adaptation because of differences in patient characteristics between countries. For example, ESRD patients in The Netherlands start dialysis at a more favourable nutritional status than ESRD patients in the USA. Our data indicate that no favourable and significant trend in mortality alongside the differences in dialysis practice was present. However, other in-depth analyses are required to establish definitely the relationship between an early start/higher dose of dialysis and patient outcome.
Some studies have suggested that a profit in terms of reduced morbidity or better survival may be achieved by an earlier start and higher doses of dialysis. An early start of RRT has been advocated in recent years to prevent malnutrition and hence a poor clinical outcome [4,16,17]. For example, a difference in survival at a difference in the mean renal Kt/Vurea at the time of initiation dialysis of 0.4/week has been reported by Tattersall et al. [4]. This figure suggests that the observed time trend in residual renal function may be of clinical importance, as it is in the same order of magnitude. However, other studies did not confirm the more favourable outcome in patients with a high residual renal function at the start of dialysis. For instance, in a first analysis of data of NECOSAD-2 patients (n=253) an earlier start of dialysis was not associated with a more favourable survival and higher health-related quality of life [15,18]. Also, in a study by Davies et al. [19], it was strongly suggested that the decrease in residual renal function is an important predictor of mortality, but no difference in residual renal function shortly after the start of dialysis between survivors and non-survivors was found, although the mean initial value for the renal Kt/Vurea was only 0.8/week. However, a recently published registry study from Scotland also reported no beneficial effect of renal function at the start of dialysis (median creatinine clearance 8.3 ml/min) on survival [20].
Various studies have indicated that a high dose of dialysis is associated with a reduction of mortality and morbidity rates [1,2,21]. However, recent studies among PD patients have made it likely that the effect of dialysis dose for the survival was of secondary importance in comparison with the influence of residual renal function, when taken into account properly [22]. It is speculative whether this might be the explanation for the observed decline in PD dose in 2000. However, data from 2001 and 2002 are needed to examine whether the decrease in 2000 is temporary and perhaps due to a sampling error or statistical fluctuation, or is a real ongoing downward trend.
In the United States a decrease in mortality in recent years in both HD and PD patients, together with a shift towards the adequacy standards of DOQI, has been reported. It has been debated whether the trend in mortality was solely due to changes in dialysis dose, as the improvements in mortality pre-dated improvements in adequacy. The lower mortality might as well have been caused by better anaemia control, and the introduction of biocompatible dialysis membranes [23].
We conclude that there has been a tendency towards an earlier start of RRT and a higher dialysis dose in The Netherlands in recent years. The effects of this development on mortality, morbidity, quality of life and the balance between costs and benefits need further investigation.
![]() |
Acknowledgments |
---|
![]() |
Notes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|